AMRI Expands Bulk API Aseptic Manufacturing Capacity
The contract research, development, and manufacturing organization has expanded API aseptic manufacturing capacity at its Valladolid, Spain, facility.
On Nov. 30, 2017, AMRI announced that it has expanded its current bulk active pharmaceutical ingredient (API) aseptic manufacturing capacity at its facility in Valladolid, Spain. The Valladolid facility joins the company’s other aseptic API-capable facilities in Bon Encontre and Tonneins, France.
“This investment supports our intent to serve our customers’ increasing demand for aseptic APIs linked to the need for physical control of these APIs and customized packaging configuration to improve assembling with customers’ drug product production sites,” said George Svokos, chief commercial officer, AMRI, in a company press release.
Additionally, the company recently announced the addition of an aseptic pre-filled syringe line at its manufacturing facility in Albuquerque, NM to increase its healthcare service footprint.
Source: AMRI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
